Clinical Trials Logo

Thyroid Eye Disease clinical trials

View clinical trials related to Thyroid Eye Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02422368 Withdrawn - Thyroid Eye Disease Clinical Trials

The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease

Start date: September 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

ASTED (Antioxidant Supplements for TED) trial is an investigator-initiated, randomized, triple masked, clinical trial of a selected combination of vitamins and minerals versus placebo in patients with moderate to severe thyroid eye disease. The trial has a parallel-arm design.

NCT ID: NCT02393183 Withdrawn - Thyroid Eye Disease Clinical Trials

The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)

Start date: July 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED: 1. β- Carotene (30 mg) 2. Vit C (100 mg) 3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU 4. Calcium phosphate dihydrate (40 mg) 5. Zinc oxide (4 mg, elemental) 6. Copper gluconate (3.5 mg) 7. Sodium selenite 23 mg= Selenium 100 µg 8. Nicotinamide (a form of vit.B3) (10 mg) in patients with mild Thyroid eye disease according to EUGOGO classification. To be given twice a day.

NCT ID: NCT01927406 Withdrawn - Glaucoma Clinical Trials

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Start date: June 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims to determine if PA would change the course of the orbitopathy in TED patients by altering the progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease and elevated intraocular pressure will be randomised to the PA treatment and the other eye will serve as a control eye and will be treated with Timolol.